Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Jazz Pharmaceuticals
Sort By
Newest First
1 / 1
1 / 1
Acquisition
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
Jazz Pharmaceuticals
PR-M05-21-005-999
May 06, 2021
Study Results
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Nice Insight
PR-M03-19-NI-085
Mar 29, 2019
FDA Approval
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jazz Pharmaceuticals
PR-M11-18-NI-006
Nov 02, 2018
FDA Approval
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jazz Pharmaceuticals
PR-M10-18-NI-100
Oct 30, 2018
